https://stock.noler.com/us/stock/y-mabs-therapeutics-inc https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/accounts-payable https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/accounts-receivable https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/accrual-carrying-value-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/accrued-liabilities-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/accrued-rent-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/additional-paid-in-capital https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/allowance-for-doubtful-accounts-receivable-write-offs https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/amortization https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/aoci https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/basic-shares https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/capital-expenditures https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/cash-and-equivalents https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/cash-flow-breakdown https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/common-stock-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/comprehensive-income https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/cost-of-revenue https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/costs-and-expenses https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-liabilities https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/decrease-in-utb-is-reasonably-possible https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-offering-costs https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-bonuses https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-other https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-unrealized-currency-losses https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-liabilities-deferred-expense-other-capitalized-costs https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/deferred-tax-liabilities-unrealized-currency-transaction-gains https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/defined-contribution-plan-employer-matching-contribution-percent https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/depreciation-and-amortization https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/diluted-shares https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/disposal-group-not-discontinued-operation-gain-loss-on-disposal https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/dividends-common-stock https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/effect-of-exchange-rate-on-cash-and-restricted-cash https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/eps https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/eps-basic https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/fair-value-assets-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/financing-cash-flow https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/foreign-pretax-income https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/general-and-administrative-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/gross-profit https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/impairment-of-long-lived-assets-to-be-disposed-of https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/income-tax https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/income-taxes-paid https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-insurance-settlements-receivable https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-other-current-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/insurance-settlements-receivable-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory-noncurrent https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/inventory-write-down https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/investing-cash-flow https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/level-3-asset-transfers-into-level https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/level-3-asset-transfers-out-of-level https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/net-change-in-cash https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/net-income https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/number-of-operating-segments https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/number-of-reportable-segments https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-2 https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/oci-net-of-tax https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-cash-flow https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-costs-and-expenses https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-expenses https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-income https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-cost https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-liability https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-liability-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/other-current-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/other-noncurrent-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/payments-to-fund-longterm-loans-to-related-parties https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/preferred-shares-facts https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/preferred-stock-no-par-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/pretax-income https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/pretax-income-domestic https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/profit-loss https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/property-plant-equipment https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/public-float https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/research-and-development https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/residual-value-of-leased-asset https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/restricted-cash-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/restructuring-and-related-cost-number-of-positions-eliminated-period-percent https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/restructuring-charges https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/restructuring-reserve-current https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/retained-earnings https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/revenue https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/royalty-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/sga-expense https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/shareholders-equity https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/shares-authorized https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/shares-issued https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-award-accelerated-compensation-cost https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-based-compensation https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-issued-shares-issued-value-issued-for-services https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-exercisable-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-exercisable-number https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/tax-reconciliation-tax-credits https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/total-assets https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/total-liabilities https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/treasury-stock-cost https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/treasury-stock-retired-cost-method-amount https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/utb-decrease-from-settlements https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/y-mabs-therapeutics-inc/weighted-average-number-of-share-outstanding-basic-and-diluted